国际病理 2009, 29(2) 111-114  DOI:      ISSN: 0412-1961 CN: 21-1139/TG

本期目录 | 下期目录 | 过刊浏览 | 高级检索                                                            [打印本页]   [关闭]
论著
扩展功能
本文信息
Supporting info
PDF(870KB)
[HTML全文]
参考文献[PDF]
参考文献
服务与反馈
把本文推荐给朋友
加入我的书架
加入引用管理器
引用本文
Email Alert
文章反馈
浏览反馈信息
本文关键词相关文章
改良疾病累计评分表
非小细胞肺癌
合并症
化学治疗
本文作者相关文章
严文辉
彭新茂
杨洲
PubMed
Article by
Article by
Article by
改良疾病累计评分表在多西他赛联合顺铂化疗中的应用
严文辉, 彭新茂, 杨洲
湖南省脑科医院,湖南省第二人民医院肿瘤科,长沙 410007
摘要: 目的:应用改良疾病累计评分表(modified cumulative illness rating scale, MCIRS)评价合并症,观察晚期非小细胞肺癌(non-small-cell lung cancer, NSCLC)患者多西他赛联合顺铂化疗毒副反应发生率。方法:选择NSCLC患者60例,采用MCIRS评估合并症,根据MCIRS评分、年龄及KPS分层研究多西他赛联合顺铂化疗毒副反应发生率。结果:60例NSCLC患者MCIRS评分为2~20(9.250±3.917)分。其化疗毒副反应胃肠道反应、骨髓抑制、疲劳及脱发的发生率随MCIRS评分的升高而增高,差异具有统计学意义(P<0.05);随年龄增加和KPS评分降低而略增高,但无统计学意义(P> 0.05)。结论:MCIRS能较好地评价晚期非小细胞肺癌患者合并症,化疗毒副反应发生率随MCIRS评分的升高而增高。
关键词 改良疾病累计评分表   非小细胞肺癌   合并症   化学治疗  
Application of modified cumulative illness rating scale in chemotherapy of docetaxel and cisplatin regimen
YAN Wenhui, PENG Xinmao, YANG Zhou
Department of Oncology, Brains Hospital of Hunan Province, Second People Hospital of Hunan Province, Changsha 410007, China
Abstract: ObjectiveTo observe the incidence of chemotherapy toxicity of docetaxel and cis-platin regimen using the modified cumulative illness rating scale (MCIRS) to investigate the distribution of comorbidity in patients with the advanced non-small cell lung cancer (NSCLC). MethodsA total of 60 NSCLC patients was selected. Comorbidity was assessed with the MCIRS. The patients were stratified according to the score of MCIRS, age and karnofsky performance score (KPS) to study the incidence of chemotherapy toxicity of Docetaxel and Cisplatin regimen. ResultsThe scores of MCIRS of sixty patients with NSCLC varied from 2 to 20(9.250±3.917). With the increase of MCIRS score, the incidence of the toxicities of gastrointestinal, bone marrow, fatigue and hair losing were significantly increased in sixty patients who accepted chemotherapy. There were no changes in the incidence of toxicity when stratified by age or KPS. ConclusionMCIRS is a validated tool that can be used to evaluate comorbidity in patients with the advanced NSCLC. With the increase of MCIRS score, the occurrence rates of the toxicities were increased in the patients who accepted chemotherapy.
Keywords: modified cumulative illness rating scale  
收稿日期 2009-01-25 修回日期 2009-02-23 网络版发布日期  
DOI:
基金项目:

通讯作者: 严文辉
作者简介:
作者Email:

参考文献:
本刊中的类似文章

文章评论

Copyright by 国际病理